XIENCE 28 trial showed that XIENCE™ Stent with 1-month DAPT had no increase in ischemic events and a significantly lower rate of severe bleeding (BARC 3-5) compared with 6-month DAPT.2
XIENCE™ Stent is proven safe with 1-month and 3-month DAPT in HBR patients.2
XIENCE 28 trial results2
XIENCE™ Stent with 1-month DAPT showed no increase in ischemic events versus 6-month DAPT — all death or MI.
XIENCE 28 met its primary non-inferiority endpoint and included over 1600 high-bleeding risk patients.
XIENCE™ Stent with 1-month DAPT had a significantly lower rate of severe bleeding versus 6-month DAPT. (BARC 3-5).
For BARC 2-5 — XIENCE™ Stent with 1-month DAPT showed numerically lower bleeding rate versus 6-month DAPT.
Note: PS stratified analysis for BARC 3-5 bleeding was not pre-specified.
Note: BARC 2-5 was a powered secondary endpoint.
XIENCE™ Stent shows low ST rate2
XIENCE™ Stent with 1-month DAPT showed no increase in ST versus 6-month DAPT.
XIENCE™ Stent with 1-month DAPT had a low rate of Definite/Probable stent thrombosis of 0.3% for the 1-month DAPT group.
XIENCE™ Stent is significantly more thromboresistant than other DES.3
XIENCE™ Stent's fluoropolymer is significantly more thromboresistant than other DES
XIENCE™ Stent shows significantly (p<0.01) less platelet adhesion vs. other DES.
XIENCE 90 trial results2
XIENCE™ Stent with 3-month DAPT showed no increase in ischemic events versus 12-month DAPT — all death or MI.
XIENCE 90 met its primary non-inferiority endpoint and included over 2000 high-bleeding risk patients.
XIENCE™ Stent with 3-month DAPT had a significantly lower rate of severe bleeding versus 12-month DAPT. (BARC 3-5).
For BARC 2-5 — XIENCE with 3-month DAPT showed numerically lower bleeding rate versus 12-month DAPT.
Note: PS stratified analysis for BARC 3-5 bleeding was not pre-specified.
Note: BARC 2-5 was a powered secondary endpoint.
XIENCE™ Stent with 3-month DAPT met its performance goal for ST.
XIENCE 90 met its performance goal for ST and showed a low rate of Definite/Probable stent thrombosis of 0.2% for the 3-month DAPT group.
References
- XIENCE Skypoint™ Stent Instructions for Use (IFU). Refer to IFU for additional information.
- Mehran R, et al. J Am Coll Cardio Intv. 2021;14:1870-1883.
- Jinnouchi, H., et al. J Am Coll Cardiol. 2019;74:13 (Suppl B).
MAT-2636494 v7.0